Back To: Home : Featured Technology : High Throughput Screening

CLICK HERE FOR WHAT'S NEW IN:
 

Mount Sinai School of Medicine gets first Trilogy Instrument from U.S. Genomics
January 2005
EDIT CONNECT
SHARING OPTIONS:

WOBURN, Mass.U.S. Genomics announced late last year placement of its first Trilogy Single Molecule Analyzer, with the Life Sciences Technology Laboratory at New York's Mount Sinai School of Medicine.
 
"Mount Sinai is an international leader for cutting-edge life science and biomedical research," said Stephen P. DeFalco, chairman and chief exective officer of U.S. Genomics. "We are delighted to work with the prominent researchers of Mount Sinai and look forward to advancing scientific discovery through the use of single molecule biology on the Trilogy platform."
 
The first Trilogy platform installation includes an instrument and associated reagents to support a variety of direct, single molecule assays in a 96-well format.
 
The platform, combining advances in microfluidics, optical engineering, and novel labeling strategies, has applications for life science research, drug discovery and development, and diagnostics. By directly detecting and quantifying individual molecules of nucleic acids, including microRNA, siRNA, and proteins, the Trilogy platform allows researchers to screen their samples rapidly as well as perform validation and characterization of specific molecules of interest.
 
Code: E360105

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.